New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
04:55 EDTBLUE, BLUE, BLUE, BLUE, ACE, ACE, ACE, ACE, XLRN, XLRN, XLRN, XLRN, TGTX, TGTX, TGTX, TGTX, NVS, NVS, NVS, NVS, AGIO, AGIO, AGIO, AGIO, AG, AG, AG, AGEuropean Hematology Association to hold a conference
19th Congress of the European Hematology Association will be held in Milan, Italy on June 12-15.
News For BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG From The Last 14 Days
Check below for free stories on BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
10:37 EDTNVSInnoPharma announces launch of generic Zyprexa in Canada
Subscribe for More Information
July 29, 2014
07:19 EDTXLRNCBI to hold a conference
Subscribe for More Information
05:19 EDTNVSNovartis sees high uptake in meningitis B vaccination program
Subscribe for More Information
July 28, 2014
05:30 EDTNVSAlcon announces Simbrinza approved in EU
Subscribe for More Information
July 24, 2014
05:41 EDTNVSNovartis announces FDA acceptance of Sandoz application for filgrastim
Sandoz, a Novartis Group company, announced that the FDA has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar pathway created in the Biologics Price Competition and Innovation Act of 2009.
July 23, 2014
06:41 EDTNVSArray BioPharma shares attractive at current levels, says Piper Jaffray
Piper Jaffray says shares of Array BioPharma are attractive at current levels ahead of Phase III data readouts for binimetinib in melanoma, selumetinib in Kras-mutant lung, thyroid and uveal melanoma, and filanesib in multiple myeloma. Piper sees the biggest overhang on Array shares as being the financing requirement and it notes that binimetinib could be returned to the company from current partner Novartis (NVS). Nonetheless, it feels investors should take a "serious look" at Array and keeps an Overweight rating on the stock with a $9 price target.
July 22, 2014
16:15 EDTACEACE Limited reports Q2 P&C combined ratio 87.5%
Subscribe for More Information
16:14 EDTACEACE Limited reports Q2 operating EPS $2.42, consensus $2.23
Reports Q2 net premiums written $4.559B, net premiums earned $4.332B. Q2 revenue consensus $4.12B. Book value and tangible book value per share increased 3.8% and 3.9%, respectively, from March 31 to $90.19 and $73.77.
15:30 EDTACENotable companies reporting after market close
Subscribe for More Information
09:08 EDTTGTXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Chipotle (CMG), up 10.7%... Crocs (CROX), up 5%... Lockheed Martin (LMT), up 1.4%. ALSO HIGHER: GreenHunter Resources (GRH), up 10.3% after announcing intent to form MLP... TG Therapeutics (TGTX), up 9.5% after reporting Q2 results, preclinical study results, price target on shares raised to $19 from $13 at Brean Capital... FuelCell (FCEL), up 5.4% after announcing German government support, EUR 4.9M in research awards... Apache (APA), up 5.2% after Bloomberg says activist investor JANA Partners disclosed $1B position in the stock. DOWN AFTER EARNINGS: Harley-Davidson (HOG), down 4.1%... Travelers (TRV), down 3.4%... McDonald's (MCD), down 2.3%... Coca-Cola (KO), down 2.5%. ALSO LOWER: Amazon.com (AMZN), down 1% following downgrade to Neutral rating at Citigroup.
07:34 EDTTGTXTG Therapeutics price target raised to $19 from $13 at Brean Capital
Subscribe for More Information
July 21, 2014
18:40 EDTTGTXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
18:13 EDTTGTXTG Therapeutics to host conference call
Subscribe for More Information
16:30 EDTTGTXTG Therapeutics up 4.3% after reporting Q2 results, preclinical study results
16:15 EDTTGTXTG Therapeutics reports preliminary clinical results from TG-1101 Phase I study
TG Therapeutics announced preliminary clinical results from its ongoing Phase I study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody in combination with TGR-1202, the company's novel, once-daily PI3K delta inhibitor in patients with advanced CLL and non-Hodgkin's lymphoma. 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or greater than or equal to 80% reduction in Blood Lymphocyte Count. 4 of 5 CLL/SLL patients achieved a partial response at first assessment, including a patient relapsed from a prior BTK-inhibitor, and the 5th patient with stable disease achieved a 44% nodal reduction pending next assessment. 2 of 5 heavily pretreated DLBCL patients achieved a PR, including one patient with GCB subtype refractory to prior therapy. Combination appears well tolerated with no dose-related increases in toxicity observed among patients treated to date
16:13 EDTTGTXTG Therapeutics reports Q2 EPS (36c), consensus (24c)
Subscribe for More Information
07:38 EDTNVSNovartis management to meet with JPMorgan
Meetings to be held in Los Angeles/Pasadena on July 24 and in San Francisco on July 25 hosted by JPMorgan.
07:13 EDTTGTXUniversity of Nebraska Medical Center to hold a conference
2014 Pan Pacific Lymphoma Conference to be held in Kohala Coast, Hawaii on July 21-25.
07:11 EDTNVSInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
07:03 EDTNVSAnacor, Sandoz enter into agreement for commercialization of Kerydin in the U.S.
Anacor Pharmaceuticals (ANAC) announced that it has entered into an exclusive agreement with Sandoz, a Novartis (NVS) company, pursuant to which Sandoz will distribute and commercialize Anacorís drug KERYDIN topical solution, 5% in the United States. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN. On July 8, Anacor announced that the U.S. FDA approved the New Drug Application for KERYDIN, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today. The agreement with Sandoz entitles Anacor to upfront payments totaling $40M and an additional milestone payment of $25M expected to be paid in January 2015. Under the agreement, Sandoz and Anacor will share equally, under a long-term profit-sharing arrangement, the gross profits accrued by Sandoz on sales of KERYDIN, except that in 2015 Anacor will start receiving profit-sharing payments after the first $50M of gross profits have been accrued by Sandoz. The long-term profit-sharing arrangement includes cumulative minimum profit-sharing payments to Anacor in 2016 totaling $45M. Anacor will also have the option to repurchase all rights in KERYDIN from Sandoz on the later of three years from launch or December 31, 2017, at a price to be determined pursuant to the agreement. Under the terms of the agreement, Anacor will supply product to Sandoz at cost through Anacorís contract manufacturers, and Sandoz will be responsible for all of its selling, marketing, distribution, general and administrative costs related to the commercialization of KERYDIN. Anacor will hold the NDA and will be responsible for any further development of KERYDIN.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use